# Effect of Fluvoxamine on Cognition, Behavior, Symptoms and mRNA and Protein Expression in Schizophrenia Patients

> **NCT01832285** · NA · UNKNOWN · sponsor: **Sha'ar Menashe Mental Health Center** · enrollment: 40 (estimated)

## Conditions studied

- SCHIZOPHRENIA 1 (Disorder)

## Interventions

- **DRUG:** fluvoxamine

## Key facts

- **NCT ID:** NCT01832285
- **Lead sponsor:** Sha'ar Menashe Mental Health Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-12
- **Primary completion:** 2013-10
- **Final completion:** 2013-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2013-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01832285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01832285, "Effect of Fluvoxamine on Cognition, Behavior, Symptoms and mRNA and Protein Expression in Schizophrenia Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01832285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*